Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

医学 脂肪性肝炎 肝活检 脂肪肝 内科学 胃肠病学 纤维化 活检 石蕊 病理 疾病 物理化学 化学
作者
Yasaman Vali,Jenny Lee,Jérôme Boursier,Salvatore Petta,Kristy Wonders,Dina Tiniakos,Pierre Bédossa,Andreas Geier,Sven Francque,Mike Allison,George Papatheodoridis,Helena Cortêz-Pinto,Raluca Pais,Jean‐François Dufour,Diana Julie Leeming,Stephen A. Harrison,Yu Chen,Jeremy Cobbold,Michael Pavlides,Adriaan G. Holleboom,Hannele Yki‐Järvinen,Javier Crespo,M.A. Karsdal,Rachel Ostroff,Mohammad Hadi Zafarmand,Richard Torstenson,Kevin L. Duffin,Carla Yunis,Clifford A. Brass,Mattias Ekstedt,Guruprasad P. Aithal,Jörn M. Schattenberg,Elisabetta Bugianesi,Manuel Romero‐Gómez,Vlad Ratziu,Quentin M. Anstee,Patrick M. Bossuyt
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (8): 714-725 被引量:84
标识
DOI:10.1016/s2468-1253(23)00017-1
摘要

Background The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis-liver biopsy-is invasive and resource intensive.Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in a single cohort.As part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, we aimed to evaluate the diagnostic accuracy of 17 biomarkers and multimarker scores in detecting NASH and clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and identify their optimal cutoffs as screening tests in clinical trial recruitment.Methods This was a comparative diagnostic accuracy study in people with biopsy-confirmed NAFLD from 13 countries across Europe, recruited between Jan 6, 2010, and Dec 29, 2017, from the LITMUS metacohort of the prospective European NAFLD Registry.Adults (aged ≥18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence of other chronic liver diseases were excluded.The diagnostic accuracy of the biomarkers was expressed as the area under the receiver operating characteristic curve (AUC) with liver histology as the reference standard and compared with the Fibrosis-4 index for liver fibrosis (FIB-4) in the same subgroup.Target conditions were the presence of NASH with clinically significant fibrosis (ie, at-risk NASH; NAFLD Activity Score ≥4 and F≥2) or the presence of advanced fibrosis (F≥3), analysed in all participants with complete data.We identified thres holds for each biomarker for reducing the number of biopsybased screen failures when recruiting people with both NASH and clinically significant fibrosis for future trials.Findings Of 1430 participants with NAFLD in the LITMUS metacohort with serum samples, 966 (403 women and 563 men) were included after all exclusion criteria had been applied.335 (35%) of 966 participants had biopsy-confirmed NASH and clinically significant fibrosis and 271 (28%) had advanced fibrosis.For people with NASH and clinically significant fibrosis, no single biomarker or multimarker score significantly reached the predefined AUC 0•80 acceptability threshold (AUCs ranging from 0•61 [95% CI 0•54-0•67] for FibroScan controlled attenuation parameter to 0•81 [0•75-0•86] for SomaSignal), with accuracy mostly similar to FIB-4.Regarding detection of advanced fibrosis, SomaSignal (AUC 0•90 [95% CI 0•86-0•94]), ADAPT (0•85 [0•81-0•89]), and FibroScan liver stiffness measurement (0•83 [0•80-0•86]) reached acceptable accuracy.With 11 of 17 markers, histological screen failure rates could be reduced to 33% in trials if only people who were marker positive had a biopsy for evaluating eligibility.The best screening performance for NASH and clinically significant fibrosis was observed for SomaSignal (number needed to test [NNT] to find one true positive was four [95% CI 4-5]), then ADAPT (six [5-7]), MACK-3 (seven [6-8]), and PRO-C3 (nine [7-11]).Interpretation None of the single markers or multimarker scores achieved the predefined acceptable AUC for replacing biopsy in detecting people with both NASH and clinically significant fibrosis.However, several biomarkers could be applied in a prescreening strategy in clinical trial recruitment.The performance of promising markers will be further evaluated in the ongoing prospective LITMUS study cohort.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
聪慧板凳完成签到,获得积分10
3秒前
9秒前
buerzi完成签到,获得积分10
9秒前
魁梧的盼望完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助30
12秒前
15秒前
wzk完成签到,获得积分10
16秒前
称心翠容完成签到,获得积分10
18秒前
LaixS完成签到,获得积分10
19秒前
尊敬代亦发布了新的文献求助10
20秒前
要笑cc完成签到,获得积分10
21秒前
青珊发布了新的文献求助10
23秒前
宣宣宣0733完成签到,获得积分10
23秒前
俊逸吐司完成签到 ,获得积分10
24秒前
ttxxcdx完成签到 ,获得积分10
25秒前
胡质斌完成签到,获得积分10
25秒前
充电宝应助科研通管家采纳,获得10
28秒前
29秒前
姚怜南完成签到,获得积分10
31秒前
青珊完成签到,获得积分10
33秒前
自觉石头完成签到 ,获得积分10
34秒前
VVTTWW完成签到 ,获得积分10
36秒前
感性的寄真完成签到 ,获得积分10
38秒前
zhang完成签到,获得积分10
41秒前
44秒前
比比谁的速度快应助zhang采纳,获得50
48秒前
绿袖子完成签到,获得积分10
50秒前
57秒前
刘刘完成签到 ,获得积分10
58秒前
执着夏岚完成签到 ,获得积分10
58秒前
Xzx1995完成签到 ,获得积分10
1分钟前
Hululu完成签到 ,获得积分10
1分钟前
淡然的芷荷完成签到 ,获得积分10
1分钟前
GT完成签到,获得积分10
1分钟前
qiancib202完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
等待的幼晴完成签到,获得积分10
1分钟前
负责灵萱完成签到 ,获得积分10
1分钟前
幽默的忆霜完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022